Background: Depth of invasion is included in the staging of oral cavity malignancies in the recent 8 th edition of American Joint Committee on Cancer or tumour, node and metastasis staging system. This study analyses the impact of diffuse optical imaging (DOI) on incidence of lymph node involvement, stage migration, postoperative margin and independency. Methods: Postoperative HPE of fifty patients with oral cavity malignancy operated in our institute from January 2018 were collected. Depth of invasion and other pathological parameters were documented. DOI divided into three groups and statistical analysis done. Results: No lymph node metastasis is found in superficial tumours, 43% of intermediate thickness and 76% of deep tumours had lymph node involvement. Positive margin is seen only in patients with tumour DOI more than 0.5 cm, more than 50% of deep tumours had close margins while 75% of superficial tumours had adequate margin. Out of the 24 T3 tumours in this study 13 were upstaged due to inclusion of DOI, which would have been T2 according to the previous staging system. There is 54.1% (13 out of 24) upstaging in T3 tumours (T2 to T3), 23% (3 out of 13) in T2 (T1 to T2). There is no significant correlation between DOI and anatomical site, tumour size, tumour thickness, lymphovascular invasion and grade. Conclusions: Depth of invasion in oral cavity malignancies impacts adversely lymph node metastasis and margin status. It is an independent prognostic factor in oral cavity malignancy.
Carcinoma cervix is the second most common gynaecological cancer among women in India, with high prevalence in rural regions. Accurate staging is imperative for providing appropriate treatment. This study aims to analyse the concordance among clinical examination, examination under anaesthesia, and CECT in evaluating the clinical components of the staging. Materials and Methods: Carcinoma cervix patients with clinical examination staging upto stage lll, admitted in government royapettah hospital, department of surgical oncology between November 2017 and October 2019 were subjected to examination under spinal anaesthesia. CECT taken for all patients. Results regarding tumour size, fornix and parametrium involvement were tabulated and analysed. Results: Tumour size: In 21.2% (17/80) of patients who had bulky disease in EUA, CECT has reported tumour size as <4cm. Based on tumour size 5/81(6.2%) patients were down-staged by EUA in comparison with clinical examination. In 5% of patients (4/80) EUA upstaged tumour size in comparison with clinical examination. Fornix: Clinical examination failed to identify fornix involvement in 8 out of the 83 patients who had fornix involvement in EUA (9.6%). Parametrium: Out of 67 cases who had parametrium involvement in EUA, clinical examination failed to identify it in 5. (7.4%). In 28.3% of patients (19/67) who had parametrium involvement in EUA, there was no parametrium involvement in CECT. Among the 71 patients with parametrium involvement, 4 patients were identified only in CECT (5.6%). Out of 16 patients who had parametrium involvement upto side wall in EUA, CECT had no HUN or lateral pelvic wall in 11 patients(68.5%). Clinical examination failed to identify parametrium involvement upto side wall in 11/16 patients stage lllB according to EUA (68%). Conclusion: In significant number of patients CECT did not identify parametrium involvement, and it had very low sensitivity for identifying disease upto side wall. There is a non-significant under staging of tumour size in CECT in comparison to EUA. Clinical examination has low sensitivity for identifying parametrium involvement and its extent in comparison to EUA. There is no significant difference.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.